
The Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington has launched a research initiative called the GAME Study, recruiting participants who engage in gambling activities while taking GLP-1 receptor agonist medications—a class of drugs commonly prescribed for weight management and diabetes control.
Participants will receive compensation for their involvement in the study, which aims to explore potential correlations between GLP-1 medication use and gambling behavior. The research represents one of the first academic investigations into how increasingly popular weight-loss pharmaceuticals may intersect with addiction-related behaviors including gambling.
Market Context and Timing
GLP-1 medications, including brand names like Ozempic and Wegovy, have experienced explosive growth in public awareness and prescription rates over the past 18 months. Simultaneously, gambling participation—both in casinos and online—continues to expand across North America. The GAME Study essentially asks: as millions of Americans adopt GLP-1 medications, does their gambling engagement change, and if so, how?
The research addresses a gap in existing addiction literature. Most contemporary harm-reduction frameworks assume relatively static individual susceptibility to gambling-related problems. However, if GLP-1 medications alter impulse control, dopamine sensitivity, or behavioral reward mechanisms, then existing responsible gaming protocols may require recalibration.
Implications for Gaming Operators
For casinos and iGaming platforms, the GAME Study's findings could inform customer risk profiling and responsible gaming interventions. If the research identifies that GLP-1 users exhibit elevated gambling risk or reduced inhibitory control, operators may need to:
- Develop targeted responsible gaming messaging for this demographic
- Adjust bonus structures or promotional intensity for identified risk groups
- Enhance monitoring systems to flag customers in this category for proactive outreach
- Train customer service and compliance teams on GLP-1-related behavioral health considerations
Responsible Gaming Evolution
The research also reflects a broader evolution in harm minimization. Industry best practices increasingly rely on behavioral data, pharmaceutical history, and health status indicators to personalize responsible gaming measures. Rather than applying one-size-fits-all limits, operators can use demographic and medical information to calibrate risk management.
This approach raises privacy considerations, particularly around pharmaceutical data handling and customer consent. However, operators that proactively engage with health-related research may strengthen their regulatory standing and demonstrate commitment to evidence-based harm reduction.
What to Watch
The GAME Study's recruitment phase is now underway. Industry observers should monitor: (1) whether the study identifies significant behavioral patterns; (2) whether findings are peer-reviewed and published in addiction or gaming literature; and (3) whether major operators or gaming associations incorporate GLP-1 considerations into responsible gaming frameworks. The research could become a foundation for updated industry guidelines and regulatory expectations around pharmaceutical-behavioral health intersections.
Source: casino.org
Sofia Eriksson
Senior Reporter
Member of the iGaming Pulse editorial team. Covering industry news, analysis, and B2B developments across the global iGaming sector.


